Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow Print PDF (64K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Kore, A. R.
Right arrow Articles by Eckstein, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kore, A. R.
Right arrow Articles by Eckstein, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research Pages 4116-4120  


Sequence specificity of the hammerhead ribozyme revisited; the NHH rule
Introduction
Materials And Methods
   Materials
   Cleavage kinetics
Results
Discussion
Acknowledgements
References


Sequence specificity of the hammerhead ribozyme revisited; the NHH rule

Sequence specificity of the hammerhead ribozyme revisited; the NHH rule

Anilkumar R. Kore, Narendra K. Vaish, Ursula Kutzke and Fritz Eckstein*

Max-Planck-Institut für Experimentelle Medizin, Hermann-Rein-Straße 3, D-37075 Göttingen, Germany

Received June 25, 1998; Revised and Accepted July 27, 1998

ABSTRACT

The sequence specificity of hammerhead ribozyme cleavage has been re-evaluated with respect to the NUH rule. Contrary to previous reports it was found that substrates with GAC triplets were also cleaved. This was established in three different sequence contexts. The rate of cleavage under single turnover conditions was between 3 and 7% that of cleavage 3[prime] of GUC. Specificity of cleavage of substrates containing a central A in the cleavable triplet can be described as NAH, where N can be any nucleotide and H any nucleotide but G. As cleavage 3[prime] of NCH triplets has recently been described, the NUH rule can be reformulated to NHH.

INTRODUCTION

The sequence specificity of the hammerhead ribozyme is reported to be NUH, where N is any nucleotide, U is uridine and H is any nucleotide except guanosine (1). In the course of attempts to obtain ribozymes with different cleavage specificities by in vitro selection we also considered selecting for a ribozyme with an adenosine in the central part of the NUH triplet (2,3). On designing the substrate sequences for the selection protocol we discovered, to our surprise, that cleavage by the conventional hammerhead ribozyme could also occur 3[prime] of the GAC triplet. This observation encouraged us to re-investigate the sequence specificity of the hammerhead ribozyme reaction in more detail. The results of this study permit an expansion of the NUH rule, including A as the central nucleotide for cleavable triplets.

While this work was in progress we became aware of another study in which the central U was changed to cytidine with a concomitant change of the complementary A in the ribozyme to inosine (4). Thus the NUH rule could be rewritten as NHH, where H can be any nucleotide but G.

MATERIALS AND METHODS

Materials

Substrates and ribozymes were synthesized on an Applied Biosystems 394A DNA synthesizer. Phosphoramidites were obtained from PerSeptive (Hamburg, Germany). Purification of oligonucleotides was as reported previously (2,5). [[gamma]-32P]ATP (sp. act. ~5000 Ci/mmol) was from Amersham Buchler GmbH. T4 polynucleotide kinase and 10× reaction buffer (700 mM Tris-HCl, pH 7.6, 100 mM MgCl2, 50 mM DTT) were purchased from New England Biolabs. Siliconized Eppendorf tubes were obtained from Biozym Diagnostik (Germany). Cellstar Micro-Plate TC sterile were from Greiner Labortechnik. X-ray films (X-Omat XAR-5) were purchased from Kodak. Radioanalytical scanning was performed on a Fuji BAS 2000 Bio-Imaging Analyzer.

Cleavage kinetics

Single turnover (STO) cleavage rates kcat[prime] and Km[prime] were determined with 5[prime]-32P-labelled substrate. Rates were determined from the initial phase by increasing the ribozyme concentration until a plateau was reached. Stock solutions of 5[prime]-32P-labelled substrate and non-radiolabelled ribozyme in 50 mM Tris-HCl, pH 8.0, were heated separately at 90°C for 1 min, then cooled to 37°C for 15 min, followed by addition of MgCl2 to a final concentration of 10 mM. Reactions were initiated by addition of ribozyme solution to the solution of substrate and were carried out in a final volume of 50 µl at 37°C. However, some reactions were carried out at pH 7.5 at 25°C. Final concentrations of ribozymes ranged from 50 to 500 nM and substrate was 25 nM. A complete progress curve of cleavage of construct I was determined with 25 nM substrate and 500 nM ribozyme. Multiple turnover reactions to determine kcat and Km at pH 8.0 and 37°C were conducted with ribozyme concentrations ranging from 2.5 to 25 nM and those of substrate from 50 to 500 nM. Aliquots were removed for analysis at different time points and the reaction was quenched by addition of an equal volume of stop mix (7 M urea, 50 mM EDTA, 0.05% xylene cyanol and 0.05% bromophenol blue) in Micro-Plates with subsequent snap cooling on ice. Substrate and products were separated on a 20% polyacrylamide-7 M urea denaturing gel and analysed with a Bio-Image Analyzer. The extent of cleavage was determined from measurements of radioactivity in the substrate and the 5[prime] product bands. Data were fitted to the Michaelis-Menten and Eadie-Hofstee equations by KaleidaGraph (Synergy Software, Reading, PA). Values given in Tables 1 and 1 are the average of at least two determinations with a deviation [le]10% for kcat[prime] and [le]70% for Km[prime] values.

RESULTS

The initial observation was that a substrate with a G16.2A16.1C17 triplet could be cleaved by the conventional hammerhead ribozyme with a kcat[prime] of 0.35/min under single turnover kinetics at pH 8.0 and 37°C (Fig. 1, construct I, and Table 1). It was established that cleavage occurred after C by gel electrophoretic comparison with cleavage 3[prime] of the GUC triplet. Both product bands had the same mobility (data not shown). A complete progress curve of cleavage of construct I showed that it proceeded with a single rate constant to ~35% and with a slower rate up to 70% cleavage (Fig. 2, A and B inserts). The multiple turnover rate kcat was 0.09/min. The difference from the single turnover rate has to be explained by a contribution of the product release step, because of the extended base pairing in helix III. Following the reactions for up to 60 min, 25% of the substrate was cleaved with a single rate constant.

A mutational analysis of the triplet in construct I indicated that H17 could be changed to adenosine with only a slight effect on activity, to a kcat[prime] value of 0.28/min, whereas a change to uridine resulted in a reduction of kcat[prime] to 0.06/min and to guanosine in a loss of activity. The mutational analysis was extended to position 16.2 in the context of NAC (Table 1). A clear preference for a purine nucleoside in this position became evident, with 0.39/min for adenosine, compared with 0.35/min for guanosine. Substrates with uridine and cytidine in this position of the NAC triplet had kcat[prime] of 0.05 and 0.09/min, respectively.

Table 1. Cleavage kinetics of construct I
Tripleta (N16.2N16.1H17) kcat[prime] (per min) Km[prime] (nM)
GAC 0.356 43
GACb 0.137 22
GACc 0.09 169
GAU 0.067 26
GAA 0.288 13
GAG <0.0001 ND
AAC 0.395 62
UAC 0.054 97
CAC 0.091 30
GCC 0.007 7.0
GGC 0.002 49
GUC 4.248 228
GUCb 2.072 696
GUCd 1.580 371
GUU 1.062 271
GUA 3.740 261
GUG <0.0001 ND
ND, not determined.
STO kinetics with 10 mM MgCl2, Tris-HCl, pH 8.0, at 37°C.
aPositions N15.2N15.1 are complementary to N16.2N16.1.
bSTO kinetics with 10 mM MgCl2, Tris-HCl, pH 7.5, at 25°C.
cMultiple turnover at conditions as for STO.
dSTO kinetics with 10 mM MgCl2, Tris-HCl, pH 8.0, at 25°C.

In order to ascertain that construct I was not unusual and still accepted uridine at the central position 16.1 of the substrate, this position was permutated to all four nucleotides in the GNC context. Changes to cytidine and guanosine resulted in very poor cleavage, with kcat[prime] of 0.007 and 0.002/min, respectively, whereas with uridine the rate was highest, with a kcat[prime] of 4.24/min. This value is not very accurate, as cleavage was too fast to collect sufficient data at early time points. This GUC triplet is, of course, the classical substrate which has been examined extensively in the HH16 ribozyme (6). As our cleavage conditions at pH 8 and 37°C differed from those used by colleagues at pH 7.5 and 25°C, we also performed cleavage under these conditions for comparison. We obtained a kcat[prime] of 2.07/min, which is in good agreement with 1/min reported by them for HH16. We extended the rate determinations in construct I to GUU, GUA and GUG (kcat[prime] of 1.06, 3.74 and <0.0001/min, respectively) to compare the influence of the third nucleotide in conventional GUH cleavage with that of GAH.


Figure 1. Secondary structures of ribozyme and substrate constructs used in this study. In construct I, N is any nucleotide; N[prime], nucleotide complementary to N; H, any nucleotide but G.


Figure 2. Time dependence of cleavage of construct I, with G16.2 and A16.1, under single turnover conditions as described in Materials and Methods. Fit is to a biphasic equation, with inserts A and B showing the two rates in a semi-logmarithic plot.

As there was the possibility that cleavage 3[prime] of GAC and GAA might be sequence-dependent we also incorporated these triplets into the well-characterized ribozyme HH16 (construct II) (6). The rate of cleavage 3[prime] of GAC and GAA with kcat[prime] of 0.11 and 0.19/min, respectively, were somewhat lower than those seen in construct I (Table 2). Cleavage 3[prime] of GUC, established for comparison, had a kcat[prime] of 8.0/min, but again cleavage was too fast to be determined precisely. Conditions at pH 7.5 and 25°C, as used by Hertel et al. (6), gave a kcat[prime] of 1.05/min, which is identical to their value.

Table 2. Cleavage kinetics of construct II
Triplet (N16.2N16.1H17) kcat[prime] (per min) Km[prime] (nM)
GAC 0.116 139
GACa 0.027 22
GAA 0.195 14.85
GUC 7.895 229
GUCa 1.05 127
STO kinetics with 10 mM MgCl2, Tris-HCl, pH 8, at 37°C.
aSTO kinetics with 10 mM MgCl2, Tris-HCl, pH 7.5, at 25°C.

Km[prime] values were mainly determined to assess ribozyme saturation. Because of the length of helices I and II, the rapid pre-equlibrium for ribozyme-substate complex formation as required for Michaelis-Menten kinetics might not be met. The Km[prime] values varied between 13 and 97 nM for substrates with GAH and NAC triplets, where N was U, C or A in construct I, and were considerably lower than those for GUH triplets, where Km[prime] values varied between 228 and 271 nM at pH 8.0 and 37°C (Table 1). An exceptionally high Km[prime] value (696 nM) was observed for cleavage 3[prime] of GUC, determined with ribozyme concentrations up to 1000 nM. This Km[prime] was also determined at pH 7.5 and 37°C as 140 nM and at pH 8.0 and 25°C as 371 nM, indicating mainly a dependence on pH.

The observation that adenosine at position 16.1 is tolerated as a substrate is contrary to two previous reports. Cleavage has been reported to be extremely slow 3[prime] of GAC with ribozyme construct III, with a kcat[prime] of 0.002/min, and thus is essentially uncleavable (7). We repeated these experiments under identical conditions, i.e. at pH 8.0 and 37°C, and found a rate of 0.085/min. Similarly, a substrate with a GAC triplet, which was hybridized to the ribozyme by helices I and III, in the form of transcripts of 75 nt each, was reported to be resistant to cleavage (8). In order to test this finding, we reduced the construct so that ribozyme and substrate formed helices I and III with 7 and 6 bp, respectively (construct IV). The GAC substrate was cleaved very well, with a kcat[prime] of 0.52/min, comparable with cleavage of GAC in construct I.

DISCUSSION

All naturally occurring self-cleaving hammerhead structures in plant pathogenic RNAs have a uridine in the central position of the triplet sequence (9). Initial mutational studies to determine the specificity of the hammerhead reaction did not include the central uridine of the triplet until a thorough study was performed (7). The study was based on a complex where ribozyme and substrate oligoribonucleotides had been annealed via helices I and II and which had a 3 bp helix III (Fig. 1, construct III). In this structure changes from uridine to any other nucleotide resulted in a very slow cleavage rate, with a kcat[prime] of 0.002/min. We, however, determined a kcat[prime] of 0.085/min for the GAC-containing substrate, a considerably higher rate. It has been reported that it is more difficult to find substrate and ribozyme sequences for the construction of I-II complexes than for the more conventional I-III complexes, as the former tend to form stable alternative conformers (10). Because of this complication the authors pointed out that the particular construct III (Fig. 1) is unsuitable for studies involving mutant or chemically modified hammerheads. Indeed, we found by native gel analysis that substrate and ribozyme with the GAC triplet sequence only formed a complex to ~45%. It might well be that the poor cleavage reported 3[prime] of GAC was caused by complications in formation of a kinetically competent complex (10).

In another study where the GAC triplet was tested, the substrate and ribozyme were part of two transcripts of ~75 nt each (8). No cleavage 3[prime] of the GAC triplet was observed by these authors. However, re-investigating this finding with a ribozyme-substrate complex of the same sequence but with shorter helices I and III (construct IV), the substrate with the GAC triplet was cleaved quite well, with a kcat[prime] of 0.52/min. It is unclear at present what the origin of this discrepancy is, but presumably it is also a result of unfavourable folding of the transcripts. However, as in the case of construct III, other changes in the triplet reported in that publication comply with the general NUH rule.

Although several subsequent publications have investigated the cleavage efficiency of various substrate permutations of the NUH type, none seems to have questioned that uridine is an invariant nucleotide (11,12). Thus, our observation that a substrate with a GAC triplet could be cleaved in construct I (Fig. 1) came as a surprise. Cleavage was not limited to this particular triplet, but also extended to GAA and GAU, but not to GAG. Substrate cleavage with GAC and GAA triplets were also tested in the sequence context of the well-established ribozyme HH16 (construct II) (6), where they also supported cleavage, indicating that A as the central nucleotide is a more generally tolerated sequence. The time dependence of cleavage with the GAC triplet in construct I indicates that the kinetics cannot be described by a single rate constant beyond 35% cleavage, indicating that more than one conformation must be present, one of which is cleaved more slowly (Fig. 2).

The cleavage rates for the GAH triplets in construct I differed, with GAC > GAA > GAU. The same hierarchy was seen for GUH (Table 1). This is in agreement with observations by others (11-13). Even though the absolute values are not the same from the various studies, it is clear that there is an influence by the third nucleotide and the ranking of cleavage efficiencies for NAH is in general agreement with that found with the NUH triplet. The cleavage rate 3[prime] of the GAC triplet in construct I at pH 7.5 and 25°C is ~7% of that 3[prime] of the GUC triplet. A comparison of rates determined under these conditions is more reliable than those obtained at pH 8.0 and 37°C. In construct II (HH16) the difference is larger, with the rate for GAC cleavage only 3% that of GUC under identical conditions. Thus these rates fall into the same order as those for GUU cleavage, which are ~5% of those for GUC cleavage (7,12).

It is interesting to inspect the X-ray structures of the hammerhead ribozyme to see how the new U15.1A16.1 base pair can be accommodated (14). The X-ray structure provides evidence that of the two potential H bonds in the U16.1A15.1 base pair, only one, between the 4-keto group of U16.1 and the 6-amino group of A15.1, is formed in the conventional type hammerhead. The distance for the second is not commensurate with formation of such a bond. The 2-keto group of U16.1 is also involved in interactions with the A6 ribose. Changing the U-A base pair to an A-U base pair retains the potential for H bonds between the two nucleotides, although with inversion of polarity. However, it is difficult to imagine that the interactions of U16.1 with the A6 ribose could be maintained by A15.1 or compensated for by similar interactions with U16.1. Of course, other interactions could be possible which are not seen with the GUC triplet. However, the lower activity for cleavage of GAC-containing substrates than those containing GUC triplets indicates that formation of the transition state for the former is more difficult than for the latter. The change of the U16.1 A15.1 base pair to a C16.1 I15.1 base pair without loss of activity is more conservative, as the H bond pattern has been retained, except for the inverted polarity, and the pyrimidine nucleoside 2-keto function is still in place (4).

As the exocyclic functional groups of the original U16.1 A15.1 base pair are now exchanged without complete loss of activity, it is unlikely that they are active participants in catalysis. Thus the interactions seen in the X-ray structure for U16.1 might be silent, in that they do not contribute to either binding and/or formation of the transition state. This is another example of the notion that not all interactions seen in the X-ray structure are necessarily important for the reaction. This has been assumed before because of some inconsistencies between chemical modification studies and the X-ray structure (15,16). It has been particularly nicely demonstrated for U7, which can be replaced by a pyridin-4-one nucleoside with an increase of catalytic efficiency even though it cannot entertain the H bonds found for this uridine (17).

Now that it has been established that position 16.1 can be either uridine, adenosine or cytidine, the question arises in what way these nucleotides differ from guanosine, which is not tolerated. The cause for the lack of cleavage of NUG triplets has been explained in part by the formation of three H bonds, with C3 locking the molecule in an inactive conformation, and an additional destabilization of the transition state (18). There is at present no data for NGH triplets which would permit an explanation of why G is not tolerated at this position, but it might well be that there is again at least a contribution by the three H bonds to stabilization of the ground state.

Even though the rates for cleavage of NAH-containing substrates are considerably lower than for NUH substrates, we suggest, in conjunction with the data presented for cleavage of NCH triplets (4), reformulation of the NUH triplet specificity of the hammerhead ribozyme to NHH, where H can be any nucleotide except G. This expansion of the cleavage specificity increases the application of the hammerhead ribozyme for inhibition of gene expression, as more sites in the mRNA can be targeted. Even though it might be considered a marginal extension, as only a few sites of a mRNA are generally accessible for annealing of oligonucleotides, this expansion of the triplet rule could be a considerable advantage (19,20).

ACKNOWLEDGEMENTS

This work was supported in part by the Deutsche Forschungsgemeinschaft. We thank E.Westhof (Strasbourg) for discussions.

REFERENCES

1. Birikh,K.R., Heaton,P.A. and Eckstein,F. (1997) Eur. J. Biochem., 245, 1-16. MEDLINE Abstract

2. Nakamaye,K.L. and Eckstein,F. (1994) Biochemistry, 33, 1271-1277. MEDLINE Abstract

3. Vaish,N.K., Heaton,P.A., Fedorova,O. and Eckstein,F. (1998) Proc. Natl Acad. Sci. USA, 95, 2158-2162. MEDLINE Abstract

4. Ludwig,J., Blaschke,M. and Sproat,B.S. (1998) Nucleic Acids Res., 26, 2279-2285. MEDLINE Abstract

5. Tuschl,T. and Eckstein,F. (1993) Proc. Natl Acad. Sci. USA, 90, 6991-6994. MEDLINE Abstract

6. Hertel,J.,K., Herschlag,D. and Uhlenbeck,O.C. (1994) Biochemistry, 33, 3374-3385.

7. Ruffner,D.E., Stormo,G.D. and Uhlenbeck,O.C. (1990) Biochemistry, 29, 10695-10702. MEDLINE Abstract

8. Perriman,R., Delves,A. and Gerlach,W.L. (1992) Gene, 113, 157-163. MEDLINE Abstract

9. Symons,R.H. (1992) Annu. Rev. Biochem., 61, 641-671. MEDLINE Abstract

10. Clouet-d'Orval,B. and Uhlenbeck,O.C. (1996) RNA, 2, 483-491. MEDLINE Abstract

11. Zoumadakis,M. and Tabler,M. (1995) Nucleic Acids Res., 23, 1192-1196. MEDLINE Abstract

12. Shimayama,T., Nishikawa,S. and Taira,K. (1995) Biochemistry, 34, 3649-3654. MEDLINE Abstract

13. Baidya,N. and Uhlenbeck,O.C. (1997) Biochemistry, 36, 1108-1114. MEDLINE Abstract

14. Scott,W.G., Finch,J.T. and Klug,A. (1995) Cell, 81, 991-1002. MEDLINE Abstract

15. Tuschl,T., Thomson,J.B. and Eckstein,F. (1995) Curr. Opin. Struct. Biol., 5, 296-302.

16. McKay,D.B. (1996) RNA, 2, 395-403. MEDLINE Abstract

17. Burgin,A.B., Gonzalez,C., Matulic-Adamic,J., Karpeisky,A.M., Usman,N., McSwiggen,J.A. and Beigelamn,L. (1996) Biochemistry, 35, 14090-14097. MEDLINE Abstract

18. Simorre,J.-P., Legault,P., Baidya,N., Uhlenbeck,O.C., Maloney,L., Wincott,F., Usman,N., Beigelman,L. and Pardi,A. (1998) Biochemistry, 37, 4034-4044. MEDLINE Abstract

19. Birikh,K.R., Berlin,Y.A., Soreq,H. and Eckstein,F. (1997) RNA, 3, 429-437. MEDLINE Abstract

20. Eckstein,F. (1998) Nature Biotechnol., 16, 24.


*To whom correspondence should be addressed. Tel: +49 551 3899 274; Fax: +49 551 3899 388; Email: eckstein@mail.mpiem.gwdg.de


This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: www-admin{at}oup.co.uk
Last modification: 29 Aug 1998
Copyright©Oxford University Press, 1998.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
Y. Takagi, M. Warashina, W. J. Stec, K. Yoshinari, and K. Taira
SURVEY AND SUMMARY: Recent advances in the elucidation of the mechanisms of action of ribozymes
Nucleic Acids Res., May 1, 2001; 29(9): 1815 - 1834.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
G. Ferbeyre, V. Bourdeau, M. Pageau, P. Miramontes, and R. Cedergren
Distribution of Hammerhead and Hammerhead-like RNA Motifs Through the GenBank
Genome Res., July 1, 2000; 10(7): 1011 - 1019.
[Abstract] [Full Text]


Home page
Nucleic Acids ResHome page
J. Li, W. Zheng, A. H. Kwon, and Y. Lu
In vitro selection and characterization of a highly efficient Zn(II)-dependent RNA-cleaving deoxyribozyme
Nucleic Acids Res., January 15, 2000; 28(2): 481 - 488.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
S. Ambrós, C. Hernández, and R. Flores
Rapid generation of genetic heterogeneity in progenies from individual cDNA clones of peach latent mosaic viroid in its natural host
J. Gen. Virol., August 1, 1999; 80(8): 2239 - 2252.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Print PDF (64K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Kore, A. R.
Right arrow Articles by Eckstein, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kore, A. R.
Right arrow Articles by Eckstein, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?